About: Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.27 (-13.13%)
PPCB NASDAQ Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc. Common Stock share price
PPCB price activity
Last Price
$0.270
Change (24hr)
-0.04 USD (13.13%)
Volume
201.14K
Volume (4w avg)
-
Open
$0.29
Day Range
$0.27 - $0.30
Previous Close
$0.32
Last Trade
22 Oct, 8:24 pm GMT+0
Delayed
22 Oct, 8:24 pm GMT+0
PPCB price performance
Delayed
22 Oct, 8:24 pm GMT+0
PPCB Market Signals